杜瓦卢马布
吉西他滨
医学
内科学
耐受性
肿瘤科
顺铂
临床终点
不利影响
癌症
临床试验
化疗
无容量
免疫疗法
作者
Margherita Rimini,Silvia Foti,Silvia Camera,Federico Rossari,Francesco Vitiello,Federica Lo Prinzi,Luca Aldrighetti,Francesco De Cobelli,Federica Pedica,Paolo Giorgio Arcidiacono,Mara Persano,Stefano Cascinu,Andrea Casadei‐Gardini
出处
期刊:Oncology
[Karger Publishers]
日期:2024-12-06
卷期号:103 (8): 677-698
被引量:3
摘要
This real-world analysis largely confirmed the TOPAZ-1 findings, supporting gemcitabine, cisplatin, and durvalumab as a first-line standard of care for patients with advanced BTC.
科研通智能强力驱动
Strongly Powered by AbleSci AI